Taken together, these data suggest that elevated levels of KSR1 in human tumours may reduce the efficacy of KRAS inhibitors due to the ability of KSR proteins to activate the MAPK in a RAS‐independent manner. This evidence concerns the gene KRAS and neoplasm.